Desmopressin Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 0.1 mg, 0.2 mg
Reference Brands: DDAVP(US & EU)
Category:
Blood Disorder
Desmopressin tablets are synthetic analogs of vasopressin that stimulate kidneys to reabsorb water, reducing urine production. They are used to treat diabetes insipidus, manage bedwetting, and control bleeding in hemophilia A and von Willebrand disease. Benefits include decreased urination, improved hydration, and reduced bleeding risks.
Desmopressin tablet is available in Tablet
and strengths such as 0.1 mg, 0.2 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Desmopressin tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Desmopressin tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Desmopressin tablets are approved in both the US and EU, supported by comprehensive dossiers demonstrating safety, efficacy, and quality in accordance with GMP standards. In the US, the FDA regulates desmopressin products, while the EMA oversees approval in the EU. Dossiers include clinical trial data, stability, manufacturing, and safety profiles. Used primarily for diabetes insipidus, bedwetting, and bleeding disorders, desmopressin undergoes rigorous evaluation before market authorization. For detailed regulatory insights, licensing procedures, and approved dossiers of desmopressin tablets, visit Pharmatradz. Stay informed on the latest global regulatory updates for this vital therapeutic agent.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing